Why pharmaceutical culture makes AI transformation harder – and what to do about it

The precision paradox

Pharmaceutical organisations face a challenge that technology consultancies rarely understand: their greatest strength in drug development becomes their biggest barrier to AI adoption.

Precision matters in pharma. Accuracy is non-negotiable. When you’re developing therapies that affect patient health, designing clinical trials, or managing regulatory submissions, “good enough” genuinely isn’t acceptable. The industry has built cultures, systems and reward structures around getting things right – first time, every time. And this is where life science consulting typically focuses: optimising processes, deploying technology, establishing governance.

But now these precision-driven organisations must embrace AI transformation, which demands learning to work productively with tools that are imperfect today and will be different tomorrow. This culture clash plays out most acutely at the middle leadership layer – where the tension between “champion precision” and “champion experimentation” becomes impossible to ignore.

Why middle leaders bear the greatest burden

Middle leaders in pharmaceutical organisations occupy a uniquely difficult position during AI transformation. They must:

• Translate unspecific aspirations into specific actions: When the CEO announces “we’re becoming an AI-enabled organisation,” middle leaders must determine what this means for their team’s daily work.
• Model behaviours they’re still learning: How do you demonstrate confident AI usage when you’re genuinely uncertain? How do you create psychological safety for your team’s questions when you have the same questions yourself?
• Balance competing cultural imperatives: Maintain rigorous standards and delivery of results while encouraging experimentation. Move quickly while ensuring compliance.
• Manage their own vulnerability: Many pharmaceutical middle leaders built distinguished careers in pre-digital environments. They’re often a role or two away from retirement. They must now champion transformation that may feel foreign to everything that made them successful.

The result is what we call middle-layer paralysis. Strategic direction exists above. Enthusiasm exists below. But in the middle – where implementation happens – transformation stalls.

Three culture clashes that create paralysis

1. Perfection vs. iteration – Pharma trains people to wait for 100% confidence before proceeding. AI transformation requires learning with imperfect solutions. We constantly see teams hesitate because tools “aren’t accurate enough yet.” This sounds prudent but often masks cultural discomfort. AI tools will never feel finished – they evolve continuously. Organisations that succeed extract value from imperfect tools while they’re learning, rather than waiting for perfection that never arrives. Middle leaders need support making this mindset shift themselves before they can guide their teams through it.
2. Expertise vs. learning – Pharma rewards deep expertise. AI transformation requires admitting what you don’t know. Many pharmaceutical middle leaders reached their positions by becoming recognised experts. Expertise brought authority. Questions were answered, not asked. AI transformation inverts this dynamic. Suddenly, leaders must learn publicly, ask “basic” questions and acknowledge uncertainty. For many, this feels like losing the expertise that defined their professional identity. Without support, they inadvertently slow transformation because acknowledging uncertainty feels too risky.
3. Compliance vs. experimentation – Pharma operates within strict regulatory frameworks. AI transformation requires structured experimentation. We frequently hear “compliance won’t allow that” when, upon investigation, compliance concerns are either solvable with proper governance or don’t actually apply to the use case. The compliance objection becomes shorthand for “this makes me uncomfortable”. Middle leaders need frameworks for distinguishing genuine compliance constraints from cultural hesitation – and confidence to have nuanced conversations about both.

Why technology deployment alone fails

Technology consultancies typically approach AI transformation through a technical lens: deploy systems, provide training, establish governance, measure usage.

This approach misses the deeper challenge. You cannot solve culture clash through better technology. You cannot address leadership vulnerability through clearer process documentation. You cannot create psychological safety for teams when their leaders don’t feel safe themselves.

These are people challenges that require people-focused solutions.

The Insocius approach: addressing the human side of transformation through coaching pharma leaders

At Insocius, we take a fundamentally different approach to AI transformation in pharmaceutical organisations. While technology consultancies or traditional change management in healthcare can focus on systems and processes, we focus on the people who must lead the change – particularly those middle leaders navigating the culture clash between pharma’s precision imperative and AI’s requirement for continuous learning.

Our coaching-led methodology is built on the recognition that sustainable transformation happens when leaders develop genuine confidence and capability, not when they’re pushed to adopt tools they don’t understand or champion changes that feel inauthentic to their leadership style.

This approach creates conditions for leaders to navigate cultural tensions by working through them authentically.

What coaching-led transformation unlocks

Our work starts from a different premise: middle-layer paralysis stems from genuinely difficult challenges, not from lack of commitment or capability. Leaders who hesitate aren’t resistant – they’re navigating complex tensions without adequate support. This is where pharma leadership coaching proves essential. Leaders need structured space to:

• Develop authentic AI literacy: Genuine understanding of how AI works and where it adds value in their specific context. This takes time and must happen at each leader’s own pace and in an environment where they feel safe to learn.
• Process their own concerns privately: Many leaders have legitimate anxieties about AI: Will my expertise become obsolete? How do I lead when I don’t fully understand the technology? Coaching creates protected space to explore questions leaders cannot ask publicly.
• Experiment with manageable stakes: Leaders need opportunities to try AI tools, fail safely, and build confidence through direct experience. We’ll start with one of your day-to-day pain points (professional or personal) and figure out together how AI can solve it. This isn’t training – it’s structured discovery.
• Make strategic trade-offs explicitly: Someone must decide what stops to create capacity for AI learning. Coaching helps leaders develop rationale and confidence to prioritise transformation even when it feels disruptive.
• What changes when middle leaders unlock

When middle leaders gain confidence to champion AI authentically, several shifts occur simultaneously:

• Vision becomes specific: “Everyone should use AI” becomes “Our medical information team will pilot AI-assisted response drafting for standard queries, with human review, measuring quality and time savings over three months.”
• Permission spreads downward: When leaders model learning publicly – asking questions, acknowledging mistakes, celebrating productive failures – their teams do the same.
• Adoption accelerates organically: Teams see AI as how their trusted leader approaches work, making experimentation psychologically acceptable.
• Barriers surface and get addressed: Genuine obstacles get distinguished from cultural hesitation.
• Metrics shift from vanity to value: Focus moves from activity (“X% of employees logged into the AI platform”) to outcomes (“We reduced standard response time by 40% and reallocated capacity to complex scientific inquiries that require human expertise”).

This is why organisations that achieve enterprise AI impact don’t just deploy impressive systems – they invest in leadership capability at the layer where translation from strategy to action happens.

The path forward for pharmaceutical leaders

If your AI transformation has stalled despite having sophisticated technology and C-suite commitment, the solution isn’t to push harder – it’s to look deeper. Ask yourself:

• Have we created safe space for middle leaders to acknowledge what they don’t understand?
• Have we given them time to build genuine AI literacy at their own pace?
• Have we helped them translate broad aspiration into specific, actionable guidance?
• Have we addressed the culture clash between precision and experimentation explicitly?
• Do they have support navigating their own vulnerability while guiding their teams?

If the honest answer to any of these is no, the solution isn’t better technology or clearer KPIs. It’s investing in coaching-led transformation that addresses the people-side challenges technology deployment cannot solve.

The pharmaceutical companies achieving enterprise-wide AI impact understand something their competitors miss: middle-layer confidence is the bottleneck. Unlock that, and transformation scales.

Insocius provides performance coaching for pharma leaders to help them develop the confidence and capability to champion AI transformation authentically. Our coaching-led approach addresses the culture clash between pharma’s precision imperative and AI’s requirement for learning with imperfect tools – building sustainable leadership capability that technology consultancies typically miss. Ready to discuss how we can support your middle leadership layer? Please get in touch.